

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	7	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	8	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	9	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	10	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	11	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	12	OCT 19	E-mail format enhanced
NEWS	13	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	14	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	15	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	16	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	17	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	18	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	19	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	20	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	21	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	22	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	23	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	24	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	25	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	26	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	27	DEC 18	CA/CAplus patent kind codes updated
NEWS	28	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	29	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	30	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

NEWS PRICE STN 2007 Prices

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 15:24:40 ON 29 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:25:04 ON 29 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2006 HIGHEST RN 916479-39-5

DICTIONARY FILE UPDATES: 28 DEC 2006 HIGHEST RN 916479-39-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10552493.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

6-10

ring bonds :

1-5 1-2 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

1-5 1-2 6-10 10-11 10-14 11-12
 exact bonds :
 2-3 3-4 12-13 13-14
 normalized bonds :
 4-5 4-6 5-9 6-7 7-8 8-9
 isolated ring systems :
 containing 1 : 10 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:25:34 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS 4 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 56 TO 504
 PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 15:25:41 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 240 TO ITERATE

100.0% PROCESSED 240 ITERATIONS 86 ANSWERS
 SEARCH TIME: 00.00.01

L3 86 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
166.94	167.15

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:25:45 ON 29 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Dec 2006 VOL 146 ISS 2
FILE LAST UPDATED: 28 Dec 2006 (20061228/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:1093832 CAPLUS

DOCUMENT NUMBER: 145:438607

TITLE: Process for preparing heterocyclylpyrrolopyridines and their use as antagonists of corticotropin-releasing factor (CRF) receptors.

INVENTOR(S): Andreotti, Daniele; Bacchi, Sergio; Delpogetto, Monica; Guelfi, Simone; Perboni, Alcide; Ribecai, Arianna; Spada, Simone; Stabile, Paolo; Tampieri, Marsia

PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc, USA; Neurocrine Biosciences Inc

SOURCE: PCT Int. Appl., 42pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108689	A2	20061019	WO 2006-EP3480	20060406
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: GB 2005-7195

A 20050408

OTHER SOURCE(S): MARPAT 145:438607

GI



AB A process for preparation of title compds. [I; R = (substituted) aryl, heteroaryl; R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, halo, amino, cyano; R2 = H, cycloalkyl, R9; R3 = cycloalkyl, R9; R9 = (substituted) alkyl; R2R3N = (substituted) 5-14 membered heterocycle] comprises treatment of (II; X = halo; R, R1 as above) with a Cu catalyst and a reactive derivative of the residue NR2R3. Thus, CuI and trans-N,N'-1,2-diaminocyclohexane were stirred together for 2-12 h in NMP; K2CO3, 2-(1H-pyrazol-3-yl)thiazole (preparation given), and 3-iodo-6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (preparation given) in NMP were added followed by heating at 125° for 12-18 h to give 70% 6-methyl-1-[2-methyl-4-(methoxy)phenyl]-4-[3-(thiazol-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine.


IT 912848-66-9P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclylpyrrolopyridines and their use as antagonists of corticotropin-releasing factor (CRF) receptors)

RN 912848-66-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[5-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




IT 491864-38-1P 491864-40-5P 491864-41-6P
491864-42-7P 491864-46-1P 491865-57-7P
491865-58-8P 491865-59-9P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of heterocyclylpyrrolopyridines and their use as antagonists of corticotropin-releasing factor (CRF) receptors)


RN 491864-38-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491864-40-5 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 491864-41-6 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 491864-42-7 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491864-46-1 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-57-7 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(4-morpholinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 491865-58-8 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 491865-59-9 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol]-1'-yl-1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:1093785 CAPLUS
 DOCUMENT NUMBER: 145:438617
 TITLE: Process for preparation of heterocyclylpyrrolopyridines from halopyrrolopyridines using copper catalysts.
 INVENTOR(S): Bacchi, Sergio; Delpogetto, Monica; Guelfi, Simone; Perboni, Alcide; Ribecai, Arianna; Stabile, Paolo; Tampieri, Marsia
 PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc, USA; Neurocrine Biosciences Inc
 SOURCE: PCT Int. Appl., 37pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108693	A2	20061019	WO 2006-EP3531	20060406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:



GB 2005-7198

A 20050408

OTHER SOURCE(S):

MARPAT 145:438617

GI



AB Title compds. [I; R = (substituted) aryl, heteroaryl; R1 = H, cycloalkyl, alkyl, alkoxy, thioalkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, halo, amino, cyano; D = CR8R9, CR8; G = CR10R11, CR10; R8-R11 = H, cycloalkyl, alkyl, alkenyl, alkynyl, amino, cyano; dotted line = optional double bond; Z = (substituted) heterocyclyl; W = (substituted) carbocyclyl in which 1 C atom is replaced by CO, SOm, or 1-4 C atoms may be replaced by O, N, imino, CO, SOm, CO; m = 0-2], were prepared by treatment of (II; X = halo; R, R1 as above) with a reactive derivative of WZ (variables as above) catalyzed by Cu. Thus, CuI and trans-N,N'-dimethyl-1,2-diaminocyclohexane were stirred together in DMF for 2-12 h; K2CO3, 1-(1H-pyrazol-3-yl)-2-imidazolidinone (preparation given), and 3-bromo-6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridine (preparation given) in DMF were added followed by heating at 125° for 36-42 h to give 70% 1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one.


IT 491864-40-5P 491864-46-1P 786701-13-1P,
 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-15-3P,
 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methylimidazolidin-2-one
 786701-17-5P, 1-[1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one
 786701-22-2P 786701-25-5P 786701-27-7P
 786701-29-9P, 1-[1-[6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-62-0P
 786701-66-4P 786701-69-7P 786701-72-2P
 786701-75-5P 786701-77-7P 786701-79-9P
 786701-80-2P 786701-83-5P 912850-56-7P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of heterocyclylpyrrolopyridines from halopyrrolopyridines using copper catalysts)


RN 491864-40-5 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 491864-46-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 786701-13-1 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-15-3 CAPLUS


CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-17-5 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[1-(2,4-dichlorophenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-22-2 CAPLUS
 CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 786701-25-5 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-27-7 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-29-9 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-62-0 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-66-4 CAPLUS

CN 2-Pyrrolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-69-7 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydro- (9CI) (CA INDEX NAME)




RN 786701-72-2 CAPLUS

CN 2-Oxazolidinone, 3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-75-5 CAPLUS

CN 1,2,5-Thiadiazolidine-2-carboxylic acid, 5-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, methyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 786701-77-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 786701-79-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI)
(CA INDEX NAME)




RN 786701-80-2 CAPLUS

CN 2(1H)-Pyridinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-83-5 CAPLUS

CN 2H-Imidazol-2-one, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 912850-56-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:927207 CAPLUS

DOCUMENT NUMBER: 141:395557

TITLE: Preparation of condensed heterocycles as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD

INVENTOR(S): Andreotti, Daniele; Bernasconi, Giovanni; Castiglioni, Emiliano; Contini, Stefania; Di Fabio, Romano; Fazzolari, Elettra; Feriani, Aldo; Gentile, Gabriella; Mattioli, Mario; Mingardi, Anna; Sabbatini, Fabio; St.-Denis, Yves

PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094420	A1	20041104	WO 2004-IB1350	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004232551	A1	20041104	AU 2004-232551	20040407
CA 2521929	A1	20041104	CA 2004-2521929	20040407
EP 1611133	A1	20060104	EP 2004-726237	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009117	A	20060328	BR 2004-9117	20040407
CN 1805958	A	20060719	CN 2004-80016189	20040407
JP 2006522799	T	20061005	JP 2006-506558	20040407
NO 2005005238	A	20060109	NO 2005-5238	20051108
PRIORITY APPLN. INFO.:			GB 2003-8208	A 20030409
			US 2003-485322P	P 20030707

OTHER SOURCE(S):
GI

MARPAT 141:395557




AB Title [(pyrrolo[2,3-b]pyridinyl)pyrazolyl]imidazolidinones and related compds. I [wherein D = CR8R9, CR8; G = CR10R11, CR10; W = (un)substituted carbocyclyl, heterocyclyl; X = C, N; Y = N, CR7; Z = (un)substituted heterocyclyl, Ph; R = (un)substituted (hetero)aryl; R1 = H, (cyclo)alkyl, (halo)alkoxy, alkylthio, alkenyl, alkynyl, halo(alkyl), halo, NR3R4, CN; R3, R4 = independently H, alkyl; R7 = H, (halo)alkyl, halo; R8-R11 = independently H, (cyclo)alkyl, alkenyl, alkynyl, NR3R4, CN; and stereoisomers, prodrugs and pharmaceutically acceptable salts, or solvates thereof] were prepared as corticotropin-releasing factor (CRF) antagonists. For example, 4-iodo-6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine was coupled with 1-(1H-pyrazol-3-yl)imidazolidin-2-one (preparation of reactants given) in the presence of CuI, K2CO3, dodecane, and trans-cyclohexanediamine in anh. NMP to afford II (53%). In binding assays using recombinant human CRF1 and CRF2 receptors expressed in CHO cell membranes, compds. of the invention showed affinity for CRF receptors with Ki values of <10 μ M. Thus, I and their pharmaceutical compns. are useful for the treatment of depression, anxiety, IBS, and IBD (no data).

IT 786701-13-1P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (CRF antagonist; preparation of [(pyrrolopyridinyl)pyrazolyl]imidazolidinone s and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)

RN 786701-13-1 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



IT 786701-15-3P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methylimidazolidin-2-one 786701-17-5P, 1-[1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-19-7P, 1-[1-[1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-20-0P, 1-[1-[1-(4-Hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-22-2P, 1-Acetyl-3-[1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-25-5P, 1-[1-[1-[4-(Ethyloxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-27-7P, 1-[1-[6-Methyl-1-[2-methyl-4-[(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-29-9P, 1-[1-[6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-31-3P, 3-Methyl-4-[6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786701-34-6P, 1-[1-[6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-35-7P, 4-[6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile 786701-37-9P, 1-[1-[1-[2-(Difluoromethyl)-4-(methyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-40-4P, 4-[6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-[(trifluoromethyl)oxy]benzonitrile 786701-43-7P, 3-Ethyl-4-[6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786701-44-8P, 1-[1-[6-Methyl-1-[2-(methyloxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-46-0P, 1-[1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-49-3P, 1-[1-[6-Methyl-1-[2,4,6-tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-57-3P, 1-[1-[2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-62-0P, 1-[5-Methyl-1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-64-2P, 1-[1-[1-[4-[(Difluoromethyl)oxy]-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-66-4P,


1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]pyrrolidin-2-one 786701-69-7P,
 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydropyrimidin-2(1H)-one
 786701-72-2P, 3-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-oxazolidin-2-one 786701-75-5P 786701-77-7P, 4-[3-(1,1-Dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine
 786701-79-9P, 4-[3-(1,1-Dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 786701-80-2P, 3-Methyl-1-[1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2(1H)-pyridinone 786701-81-3P, 2-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3(2H)-pyridazinone 786701-83-5P, 1-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro-2H-imidazol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CRF antagonist; preparation of [(pyrrolopyridinyl)pyrazolyl]imidazolidinone s and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)


RN 786701-15-3 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-17-5 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-(2,4-dichlorophenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-19-7 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-20-0 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-[2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-22-2 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-25-5 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-27-7 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-29-9 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)




RN 786701-31-3 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-34-6 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-35-7 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 786701-37-9 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 786701-40-4 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)- (9CI)
(CA INDEX NAME)




RN 786701-43-7 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)




RN 786701-44-8 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-46-0 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-49-3 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(2,4,6-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-57-3 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-62-0 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-64-2 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-[4-(difluoromethoxy)-2-methylphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-66-4 CAPLUS

CN 2-Pyrrolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-69-7 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydro- (9CI) (CA INDEX NAME)




RN 786701-72-2 CAPLUS

CN 2-Oxazolidinone, 3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-75-5 CAPLUS

CN 1,2,5-Thiadiazolidine-2-carboxylic acid, 5-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, methyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 786701-77-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 786701-79-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI)
(CA INDEX NAME)




RN 786701-80-2 CAPLUS

CN 2(1H)-Pyridinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-81-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 786701-83-5 CAPLUS

CN 2H-Imidazol-2-one, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro- (9CI) (CA INDEX NAME)




- IT. 786700-23-0P, N-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]acetamide
 786700-24-1P, 1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-amine
 786700-25-2P 786700-26-3P, 2-[[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]ethanol 786700-27-4P, 3-[[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]-1-propanesulfonic acid 786700-28-5P, Phenyl
 [1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]carbamate 786700-29-6P,
 1-(2,2-Diethoxyethyl)-3-[1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]urea
 786700-34-3P, 1-Acetyl-3-[1-[1-(4-hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-35-4P, 1-Acetyl-3-[1-[1-[4-(ethyloxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-36-5P,
 1-Acetyl-3-[1-[6-methyl-1-[2-methyl-4-[(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone
 786700-37-6P, 1-(1-Methylethyl)-3-[1-[6-methyl-1-[2-methyl-4-[(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-48-9P,
 1-[1-[6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786700-51-4P,
 3-Methyl-4-[6-methyl-4-[3-[3-[[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786700-54-7P, 1-[1-[6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone
 786700-57-0P, 4-[6-Methyl-4-[3-[3-[[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile 786700-60-5P,
 1-[1-[1-[2-(Difluoromethyl)-4-(methyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786700-64-9P,
 4-[6-Methyl-4-[3-[3-[[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-[(trifluoromethyl)oxy]benzonitrile 786700-67-2P,
 3-Ethyl-4-[6-methyl-4-[3-[3-[[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786700-71-8P, 1-[1-[6-Methyl-1-[2-(methyloxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone
 786700-74-1P, 1-[1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-

dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786700-77-4P,
 1-[[4-(Methyloxy)phenyl]methyl]-3-[1-[6-methyl-1-[2,4,6-tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-81-0P,
 1-[1-[1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786701-03-9P,
 1-[1-[2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786701-09-5P,
 5-Methyl-1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-amine 786701-11-9P,
 1-Acetyl-3-[1-[1-[4-[(difluoromethyl)oxy]-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of [(pyrrolopyridinyl)pyrazolyl]imidazolidinones and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)


RN 786700-23-0 CAPLUS

CN Acetamide, N-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786700-24-1 CAPLUS

CN 1H-Pyrazol-3-amine, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 786700-25-2 CAPLUS

CN Glycine, N-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 786700-26-3 CAPLUS

CN Ethanol, 2-[[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 786700-27-4 CAPLUS

CN 1-Propanesulfonic acid, 3-[[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 786700-28-5 CAPLUS

CN Carbamic acid, [1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 786700-29-6 CAPLUS

CN Urea, N-(2,2-diethoxyethyl)-N'-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)




RN 786700-34-3 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)




RN 786700-35-4 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786700-36-5 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786700-37-6 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 786700-48-9 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Me

RN 786700-51-4 CAPLUS
 CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


Me

RN 786700-54-7 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-57-0 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-60-5 CAPLUS
CN 2-Imidazolidinone, 1-[1-[1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786700-64-9 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 786700-67-2 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)





Et

RN 786700-71-8 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 786700-74-1 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 786700-77-4 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(2,4,6-trimethoxyphenyl)-
 1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-
 methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-81-0 CAPLUS
CN 2-Imidazolidinone, 1-[1-[1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

CF3


RN 786701-03-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 786701-09-5 CAPLUS
 CN 1H-Pyrazol-3-amine, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl- (9CI) (CA INDEX NAME)



RN 786701-11-9 CAPLUS
 CN 2-Imidazolidinone, 1-acetyl-3-[1-[1-[4-(difluoromethoxy)-2-methylphenyl]-2-methylphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:610082 CAPLUS

DOCUMENT NUMBER: 141:157105

TITLE: Preparation of heteroaryl-substituted pyrrolo[2,3-b]pyridine derivatives as CRF receptor antagonists

INVENTOR(S): Castiglioni, Emiliano; Di Fabio, Romano; Feriani, Aldo; Micheli, Fabrizio; Sabbatini, Fabio; St-Denis, Yves

PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.; Glaxo Group Limited

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062665	A1	20040729	WO 2004-EP409	20040114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
EP 1583531	A1	20051012	EP 2004-701955	20040114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515334	T	20060525	JP 2006-500001	20040114
PRIORITY APPLN. INFO.:			US 2003-440432P	P 20030116
			WO 2004-EP409	W 20040114
OTHER SOURCE(S):		MARPAT 141:157105		
GI				



AB Pyrrolo[2,3-b]pyridines of formula I [R = aryl, heteroaryl; R1 = H, cycloalkyl, alkyl, alkoxy, CN, etc.; NR2R3 = (substituted) aromatic heterocycle; R4 = H, alkyl, halo, haloalkyl] are described, including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, processes for their preparation, pharmaceutical compns. containing them

and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF). Thus, II was prepared in several steps.


IT 727992-87-2P 727992-88-3P 727992-89-4P
 727992-90-7P 727992-91-8P 727992-92-9P
 727992-93-0P 727992-94-1P 727992-95-2P
 727992-96-3P 727992-97-4P 727992-98-5P
 727992-99-6P 727993-00-2P 727993-01-3P
 727993-02-4P 727993-03-5P 727993-04-6P
 727993-05-7P 727993-06-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl pyrrolopyridine derivs. as CRF receptor antagonists)


RN 727992-87-2 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-[6-methoxy-2-(trifluoromethyl)-3-pyridinyl]-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-88-3 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(6-methoxy-2-methyl-3-pyridinyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-89-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2,6-dimethoxy-3-pyridinyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-90-7 CAPLUS

CN 2-Pyridinamine, 5-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-N,N,4-trimethyl- (9CI) (CA INDEX NAME)




RN 727992-91-8 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 727992-92-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2-chloro-4-methoxyphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-93-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2,4-dimethoxyphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-94-1 CAPLUS

CN Benzonitrile, 3-chloro-4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-95-2 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 727992-96-3 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)




RN 727992-97-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-(4-fluoro-2-methylphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-98-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI). (CA INDEX NAME)




RN 727992-99-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[4-nitro-2-(trifluoromethyl)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727993-00-2 CAPLUS

CN Benzonitrile, 4-(4-[1,3'-bi-1H-pyrazol]-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-methyl- (9CI) (CA INDEX NAME)




RN 727993-01-3 CAPLUS

CN Benzonitrile, 4-(4-[1,3'-bi-1H-pyrazol]-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 727993-02-4 CAPLUS

CN Benzonitrile, 4-(4-[1,3'-bi-1H-pyrazol]-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-chloro- (9CI) (CA INDEX NAME)




RN 727993-03-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol]-1'-yl-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 727993-04-6 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 727993-05-7 CAPLUS

CN Benzonitrile, 3-chloro-4-[2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 727993-06-8 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 491865-06-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroaryl pyrrolopyridine derivs. as CRF receptor antagonists)

RN 491865-06-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:76778 CAPLUS

DOCUMENT NUMBER: 138:137173

TITLE: Preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists

INVENTOR(S): Di Fabio, Romano; Micheli, Fabrizio; St-denis, Yves

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003008412	A2	20030130	WO 2002-EP7865	20020715
WO 2003008412	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2378702	A	20030219	GB 2002-16041	20020711
CA 2451530	A1	20030130	CA 2002-2451530	20020715
EP 1425280	A2	20040609	EP 2002-764696	20020715
EP 1425280	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011171	A	20040810	BR 2002-11171	20020715
CN 1525972	A	20040901	CN 2002-813866	20020715
HU 200400465	A2	20050128	HU 2004-465	20020715
JP 2005514328	T	20050519	JP 2003-513971	20020715
NZ 530043	A	20060331	NZ 2002-530043	20020715
EP 1695974	A1	20060830	EP 2006-76176	20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
AT 338042	T	20060915	AT 2002-764696	20020715
ZA 2003009708	A	20050121	ZA 2003-9708	20031215
US 2004171607	A1	20040902	US 2004-483792	20040114
NO 2004000206	A	20040316	NO 2004-206	20040116
PRIORITY APPLN. INFO.:			GB 2001-17396	A 20010717

OTHER SOURCE(S): MARPAT 138:137173
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines [I; wherein R = (substituted) aryl, heteroaryl; R1 = H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, halogen, amino, or cyano; R2 = H, (C3-C7)cycloalkyl; R3 = (C3-C7)cycloalkyl; or R2 and R3 together with N form a (substituted) 5-14 membered heterocycle; R4 = H, (C1-C6)alkyl, halo, halo(C1-C6)alkyl; X = C, N; n = 1 or 2] were prepared For example, compound (II) was prepared by the provided method. The prepared compds. are useful in the treatment of conditions mediated by corticotropin-releasing factor (CRF) (no data).


IT 491864-38-1P 491864-40-5P 491864-41-6P
491864-42-7P 491864-46-1P 491865-57-7P
491865-58-8P 491865-59-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists)


RN 491864-38-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491864-40-5 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 491864-41-6 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 491864-42-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491864-46-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-57-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(4-morpholinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-58-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-59-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol-1'-yl]-1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl- (9CI) (CA INDEX NAME)



IT 491865-06-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and
 tetrahydro[1,8]naphthyridines as CRF receptor antagonists)
 RN 491865-06-6 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-
 pyrazol-1-yl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:24:40 ON 29 DEC 2006)

FILE 'REGISTRY' ENTERED AT 15:25:04 ON 29 DEC 2006

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 86 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:25:45 ON 29 DEC 2006

L4 5 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

27.85

195.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY
-3.75

SESSION
-3.75

STN INTERNATIONAL LOGOFF AT 15:28:59 ON 29 DEC 2006